NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period and full year ended December 31, 2025, after the close of the market on Thursday, February 26, 2026.

Progyny (NASDAQ: PGNY - Get Free Report) and Amarantus Bioscience (OTCMKTS:AMBS - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations. Valuation and Earnings This table compares Progyny and Amarantus

Hussman Strategic Advisors Inc. acquired a new stake in Progyny, Inc. (NASDAQ: PGNY) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 105,000 shares of the company's stock, valued at approximately $2,260,000. Hussman Strategic Advisors Inc. owned about 0.12% of Progyny as of

Progyny, Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced that the Company is participating in the 44th Annual JP Morgan Healthcare Conference, where it intends to discuss its updated expectations for the quarter and year ending December 31, 2025. “As the fourth quarter progressed, we were pleased to see that member engagement has paced favorably as compared to the guidance we issued in November,” said Pete Anevski, Progyny's Chief Executive Officer.

Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Medical services stocks like MEDP, EHAB and PGNY benefit from tech-driven care models even as staffing gaps pressure margins.

Pacer Advisors Inc. reduced its holdings in Progyny, Inc. (NASDAQ: PGNY) by 28.5% in the undefined quarter, according to the company in its most recent filing with the SEC. The firm owned 385,079 shares of the company's stock after selling 153,120 shares during the quarter. Pacer Advisors Inc. owned approximately 0.45% of Progyny

Progyny (NASDAQ: PGNY - Get Free Report) and Zicix (OTCMKTS:ZICXD - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings. Volatility and Risk Progyny has a beta of 0.97, suggesting

Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.